Clinical trial
A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular…
NCT00249782 · Allergan, Industry · Completed
Key facts
| NCT number | NCT00249782 |
|---|---|
| Title | A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea. |
| Official title | A Phase II, Randomized, Partial-Blind, Parallel-Group, Active- and Vehicle-Controlled, Multicenter Study of the Safety and Efficacy of ACZONE™ (Dapsone) Gel, 5% in Subjects With Papulopustular Rosacea |
| Lead sponsor | Allergan, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Rosacea |
| Intervention type | Drug |
| Interventions | Vehicle control, 2x/day, ACZONE (dapsone) Gel, 5%, 1x/day, MetroGel® (metronidazole gel), 1.0% 1x/day, 1x/day (AM) + MetroGel (metronidazole gel), 1.0%, 1x/day (PM) |
| Enrollment | 400 |
| Start date | Nov 1, 2005 |
| Primary completion | May 1, 2006 |
| Completion | May 1, 2006 |
| First posted | Nov 7, 2005 |
| Last update posted | May 30, 2011 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: